SNP234, a novel potent, aggregate selective anti‐Aβ antibody, as next generation anti‐amyloid immunotherapy amicable for subcutaneous administration
SNP234 demonstrates high selectivity against toxic form of Aβ and promotes efficient removal of disease-associated Aβ. These findings support further development of SNP234 as a potential next generation best-in-class anti-amyloid immunotherapy agent with subcutaneous administration.
Authors
- Yuka A. Martens (ORCID: https://orcid.org/0000-0002-5194-4269)
- Mary Elizabeth Curtis (ORCID: https://orcid.org/0000-0002-9924-9257)
- Gang An (ORCID: https://orcid.org/0000-0002-4467-1928)
- Young Park
- Kevin Chen
- Min Li
- Zusheng Li
- Jakob Samsel
Institutions
- CASI Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_107093
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00